

BROWN RAYSMAN

BROWN RAYSMAN MILLSTEIN FELDER & STEINER, LLP

FACSIMILE COVER SHEET

From: James P. Demers, Esq. **Date:** October 7, 2004
Direct Dial: 212-895-2683 **Client/Matter #:** 6319-1662

PLEASE DELIVER AS SOON AS POSSIBLE TO:

James Schultz
Art Unit 1635

Fax No.
(703) 872-9306

Phone No.
(571) 272-0763

Total number of pages including this page: **3**
If you do not receive all the pages, please call **212-895-2683.**

Certificate of Transmission

RE: U.S. Patent Application No: 09/331,204

I hereby certify that the enclosed Summary of Telephone Conversation is being facsimile transmitted to the United States Patent and Trademark Office at the number shown above on October 7, 2004.


James P. Demers
Registration No: 34,320

RECEIVED
CENTRAL FAX CENTER
OCT 07 2004

Please Note: the information contained in this facsimile message is privileged and confidential, and is intended only for use of the individual named above and others who have been specifically authorized to receive it. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, or if any problems occur with transmission, please notify **sender or the mail room** by telephone: (212) 895-2000. Thank You.

BROWN RAYSMAN MILLSTEIN FELDER & STEINER LLP

900 THIRD AVE NY NY 10022 T 212-895-2000 F 212 895-2900 brownraysman.com

BRMFS1 515313v1

09/331,204

6319-1662

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Robert Tam Art Unit : 1635
Application No. : 09/331,204 Examiner : James Schultz
Filing Date : 08/20/1999
Title : G-Rich Oligo Aptamers and Methods of Modulating an Immune Response

Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

SUMMARY OF TELEPHONE CONVERSATION

Sir:

This is to confirm Applicant's consent to an Examiner's amendment to the claims, given by telephone on September 26, 2004.

We propose the following text for claims 11, 12, 14, 15, and 17:

11. An aptamer having the sequence 5' TTG GAG GGG GTG GTG GGG 3' (SEQ ID NO: 4).
12. An aptamer having the sequence 5' GGG GAG GAG GGG CTG GAA 3' (SEQ ID NO: 5).
14. An aptamer having the sequence 5' TTG GAG GGG GAG GAG GGG 3' (SEQ ID NO: 7).
15. An aptamer having the sequence 5' TTG GAG GGG GAG GTG GGG 3' (SEQ ID NO: 8).
17. A method of medicating an isolated immune competent cell, comprising administering to the cell an aptamer at a concentration effective to reduce CD28 expression, wherein the aptamer is selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 8.

09/331,204

6319-1662

REMARKS

It was agreed that, by means of an Examiner's amendment, Claims 11, 12, 14, and 15 would be simplified by deleting superfluous language in the preamble, and that Claim 17 would read upon the use of the aptamers recited in Claims 11, 12, 14, and 15. The Examiner is invited to use the claim language proposed above.


Applicant reserves the right to file claims directed to subject matter surrendered during the prosecution of this application, in continuing or divisional applications.

Respectfully submitted,

Brown Raysman Millstein Felder & Steiner, LLP

Dated: 10/7/04

by:



James P. Demers, Reg. No. 34,320

BROWN RAYSMAN MILLSTEIN FELDER & STEINER LLP
900 Third Avenue
New York, New York 10022

212-895-2000
212-895-2900 fax

- 2 -

BRMFS1 520496v1